Pulmonary Embolism (PE)NCT07009301
Pulmonary Embolism Following Viper's Bites: A Case Report
An observational study of Pulmonary Embolism (PE) and Snake Envenomation, run by Younes Oujidi at 1 site in Morocco.
Trial summary
Viper envenomation constitutes a medical emergency predominantly occurring in rural regions, where specific viper species are endemic, with their distribution influenced by climatic variations. Read more about this study
- Who is it for?
- Ages 18 to 100 years, women only
- Conditions the study is for
- Pulmonary Embolism (PE), Snake Envenomation
- How many people
- 1 participants
- Where
- 1 siteMorocco
- Study dates
- 10 Jan 2025to 20 May 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- Women only
- Adult, Older adult
Study population: People aged above 18years, developing a pulmonary embolism after snake bites
Who may be able to join
- Age above 18years old
Who cannot join
- Not bitten by snakes
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Observational Study About a Case of Pulmonary Embolism Following Viper's Bite
Viper envenomation constitutes a medical emergency predominantly occurring in rural regions, where specific viper species are endemic, with their distribution influenced by climatic variations. The literature describes numerous complications associated with viper bites, including neurological disturbance, hematological abnormalities, and irreversible renal failure.
We report the case of a 65-year-old female patient admitted to the intensive care unit for viper envenomation characterized by extensive local edema. Diagnostic investigations, including laboratory tests and imaging studies, revealed the presence of a bilateral pulmonary embolism. The patient was subsequently treated with antivenom therapy, followed by initiation of low molecular weight heparin. Despite the recognized high risk of viper envenomation described in the literature, the patient experienced an uncomplicated clinical course and was discharged in stable condition with no further complications.
- Conditions
- Pulmonary Embolism (PE), Snake Envenomation
- Medical subject headings
- Pulmonary Embolism, Snake Bites
What is being measured
The primary outcome is the main question the study is designed to answer.
Evolution of hematological blood test during the ICU stay
Measured: From January 2025 to May 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2025
- Study start10 Jan 2025
- Primary completion25 Jan 2025
- Study completion20 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pulmonary Embolism (PE)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 1 participants (actual)
Sponsor and investigators
- Lead sponsor
- Younes Oujidi
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Younes Oujidi, Mohammed VI University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07009301
- Sponsor's protocol ID
- Critial Care
- Status last verified
- May 2025
- First submitted
- 29 May 2025
- Last updated
- 6 Jun 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Observational Study About a Case of Pulmonary Embolism Following Viper's Bite
- ClinicalTrials.gov ID
- NCT07009301
- Acronym / sponsor ID
- Critial Care
- Conditions
- Pulmonary Embolism (PE), Snake Envenomation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1 participants (actual)
- Lead sponsor
- Younes OujidiUniversity, hospital or other
- Study start
- 10 Jan 2025 (actual)
- Primary completion
- 25 Jan 2025 (actual)
- Study completion
- 20 May 2025 (actual)
- First posted
- 6 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Viper envenomation constitutes a medical emergency predominantly occurring in rural regions, where specific viper species are endemic, with their distribution influenced by climatic variations. The literature describes numerous complications associated with viper bites, including neurological disturbance, hematological abnormalities, and irreversible renal failure.
We report the case of a 65-year-old female patient admitted to the intensive care unit for viper envenomation characterized by extensive local edema. Diagnostic investigations, including laboratory tests and imaging studies, revealed the presence of a bilateral pulmonary embolism. The patient was subsequently treated with antivenom therapy, followed by initiation of low molecular weight heparin. Despite the recognized high risk of viper envenomation described in the literature, the patient experienced an uncomplicated clinical course and was discharged in stable condition with no further complications.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 100 years
- Sex
- Female only
- Age groups
- Adult, Older adult
- Study population
- People aged above 18years, developing a pulmonary embolism after snake bites
Key inclusion criteria (1 listed)
- Age above 18years old
Key exclusion criteria (1 listed)
- Not bitten by snakes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Evolution of hematological blood test during the ICU stay
Time frame: From January 2025 to May 2025
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jun 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Pulmonary Embolism (PE)
RecruitingPhase 3
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Cancer-Associated Thrombosis (CAT)
RecruitingPhase 3
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Venous Thromboembolism (VTE)
RecruitingPhase 3
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
Symptomatic Venous Thromboembolism (VTE)
Not yet recruiting
CTEPH Differential Diagnosis Assisted by Enhanced Large Language Model Support
Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Acute Pulmonary Embolism (PE)
Not yet recruiting
Exclusion of Left Atrial Appendage Thrombus in Emergency Department Patients With Atrial Fibrillation Undergoing CT to Assess for Pulmonary Embolus: A Feasibility Study
Atrial Fibrillation (AF), Pulmonary Embolism (PE)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pulmonary Embolism (PE) and Snake Envenomation, run by Younes Oujidi at 1 site in Morocco.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Morocco. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evolution of hematological blood test during the ICU stay (time frame: From January 2025 to May 2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jun 2025.